GENNET LABORATORIES AS
Date of report 05.04.2025
GENNET LABORATORIES AS
Former names
- aktsiaselts Gennet Lab
start | end |
---|---|
01.01.1994 | - |
keywords
- tervishoiuinfosüsteem
- haigla infosüsteemid
- majandustarkvara
- kliinilised infosüsteemid
- tootmis- ja finantslahendused
- majandustarkvara lahendused
- tervise infosüsteemid
- ester tervisesüsteem
GENNET LABORATORIES AS
Scores and ratings
Reputation score
Credit Score
Open the reports you want to print
Employees and salaries
GENNET LABORATORIES AS
Employee taxes and performance analysisQuarter | Labor taxes paid | Number of employees | Turnover Per Employee | Profit per employee |
---|---|---|---|---|
2024 IV | ...... | ...... | ...... | ...... |
2024 III | ...... | ...... | ...... | ...... |
2024 II | ...... | ...... | ...... | ...... |
2024 I | ...... | ...... | ...... | ...... |
2023 IV | ...... | ...... | ...... | ...... |
2023 III | ...... | ...... | ...... | ...... |
2023 II | ...... | ...... | ...... | ...... |
2023 I | ...... | ...... | ...... | ...... |
2022 IV | ...... | ...... | ...... | ...... |
2022 III | ...... | ...... | ...... | ...... |
2022 II | ...... | ...... | ...... | ...... |
2022 I | ...... | ...... | ...... | ...... |
2021 IV | ...... | ...... | ...... | ...... |
2021 III | ...... | ...... | ...... | ...... |
2021 II | ...... | ...... | ...... | ...... |
2021 I | ...... | ...... | ...... | ...... |
2020 IV | ...... | ...... | ...... | ...... |
2020 III | ...... | ...... | ...... | ...... |
2020 II | ...... | ...... | ...... | ...... |
2020 I | ...... | ...... | ...... | ...... |
2019 IV | ...... | ...... | ...... | ...... |
2019 III | ...... | ...... | ...... | ...... |
2019 II | ...... | ...... | ...... | ...... |
2019 I | ...... | ...... | ...... | ...... |
2018 IV | ...... | ...... | ...... | ...... |
2018 III | ...... | ...... | ...... | ...... |
2018 II | ...... | ...... | ...... | ...... |
2018 I | ...... | ...... | ...... | ...... |
2017 IV | ...... | ...... | ...... | ...... |
2017 III | ...... | ...... | ...... | ...... |
2017 II | ...... | ...... | ...... | ...... |
2017 I | ...... | ...... | ...... | ...... |
2016 IV | ...... | ...... | ...... | ...... |
2016 III | ...... | ...... | ...... | ...... |
2016 II | ...... | ...... | ...... | ...... |
2016 I | ...... | ...... | ...... | ...... |
2015 IV | ...... | ...... | ...... | ...... |
2015 III | ...... | ...... | ...... | ...... |
2015 II | ...... | ...... | ...... | ...... |
2015 I | ...... | ...... | ...... | ...... |
Deciders and beneficiaries
GENNET LABORATORIES AS
Decision-makersFormer decision-makers
......
Credit Score: Trustworthy
Reputation score: 7180
Date of birth: ......
Active relations 7
23 followers
GENNET LABORATORIES AS
Former decision-makers......
Credit Score: Trustworthy
Reputation score: 650
Date of birth: ......
Active relations 1
49 followers
......
Credit Score: Trustworthy
Reputation score: 2380
Date of birth: ......
Active relations 6
39 followers
......
Credit Score: Trustworthy
Reputation score: 570
Date of birth: ......
Active relations 1
5 followers
......
Credit Score: Trustworthy
Reputation score: 650
Date of birth: ......
Active relations 1
49 followers
......
Credit Score: Trustworthy
Reputation score: 15360
Date of birth: ......
Active relations 9
253 followers
......
Credit Score: Neutral
Reputation score: 5050
Date of birth: ......
Active relations 4
101 followers
......
Credit Score: Trustworthy
Reputation score: 650
Date of birth: ......
Active relations 1
49 followers
GENNET LABORATORIES AS
History of right of representationGENNET LABORATORIES AS
OwnersFormer owners
Name | Credit Score | Payment | Beginning | Type | Holding |
---|---|---|---|---|---|
...... | ...... | ...... |
100%
|
Former owners
Name | Credit Score | Payment | Beginning | Ending |
---|---|---|---|---|
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... |
GENNET LABORATORIES AS
Other related partiesFormer other persons
Other related parties (invalid relations)
Name | Credit Score | Part | Beginning | Ending |
---|---|---|---|---|
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... | ||
...... | ...... | ...... |
GENNET LABORATORIES AS
Subsidiaries and associatesFormer subsidiaries and associates
Beneficiaries
Volumes and values of beneficiaries' assets
Finances and assets
GENNET LABORATORIES AS
GoodwillGENNET LABORATORIES AS
Taxes paid and estimated average salariesGENNET LABORATORIES AS
Quarterly indicatorsQuarter | Turnover | Taxed turnover | Labour productivity | Labour productivity | Employees | National taxes | Labor taxes |
---|---|---|---|---|---|---|---|
2024 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2024 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2023 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2022 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2021 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2020 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2019 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2018 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2017 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2016 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 IV | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 III | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 II | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
2015 I | * ...... | ...... | * ...... | ...... | ...... | ...... | ...... |
GENNET LABORATORIES AS
Sales revenue by business areaGENNET LABORATORIES AS
Sales revenue by countryGENNET LABORATORIES AS
Financial indicators and prognosisGENNET LABORATORIES AS
Financial raiting: "SATISFACTORY" (2024 prognosis)GENNET LABORATORIES AS
Annual reportsYear | Period | Submitted | Report PDF |
---|---|---|---|
2023 | 01.01.2023–31.12.2023 | 15.07.2024 | ...... |
2022 | 01.01.2022–31.12.2022 | 07.12.2023 | ...... |
2021 | 01.01.2021–31.12.2021 | 30.09.2022 | ...... |
2020 | 01.01.2020–31.12.2020 | 30.09.2022 | ...... |
2019 | 01.01.2019–31.12.2019 | 11.02.2021 | ...... |
2018 | 01.01.2018–31.12.2018 | 30.08.2019 | ...... |
2017 | 01.01.2017–31.12.2017 | 04.07.2018 | ...... |
2016 | 01.01.2016–31.12.2016 | 30.06.2017 | ...... |
2015 | 01.01.2015–31.12.2015 | 21.06.2016 | ...... |
2014 | 01.01.2014–31.12.2014 | 18.06.2015 | ...... |
2013 | 01.01.2013–31.12.2013 | 10.07.2014 | ...... |
2012 | 01.01.2012–31.12.2012 | 22.07.2013 | ...... |
2011 | 01.01.2011–31.12.2011 | 18.06.2012 | ...... |
2010 | 01.01.2010–31.12.2010 | 30.06.2011 | ...... |
2009 | 01.01.2009–31.12.2009 | 30.06.2010 | ...... |
2008 | 01.01.2008–31.12.2008 | 17.06.2009 | ...... |
2007 | 01.01.2007–31.12.2007 | 05.06.2008 | ...... |
2006 | 01.01.2006–31.12.2006 | 26.06.2007 | ...... |
2005 | 01.01.2005–31.12.2005 | 30.06.2006 | ...... |
2004 | 01.01.2004–31.12.2004 | 22.06.2005 | ...... |
2003 | 01.01.2003–31.12.2003 | 25.06.2004 | ...... |
2002 | 01.01.2002–31.12.2002 | 27.06.2003 | ...... |
2001 | 01.01.2001–31.12.2001 | 25.06.2002 | ...... |
2000 | 01.01.2000–31.12.2000 | 25.06.2001 | ...... |
Liabilities and debts
GENNET LABORATORIES AS
Credit score history and prognosis... €
......
Business risk classes:
Trustworthy NeutralGENNET LABORATORIES AS
Reports and assets-liabilities overview 05.04.2025GENNET LABORATORIES AS
Claims historyTotal debt claims: ...... €
...... | ...... |
GENNET LABORATORIES AS
Debt by type 05.04.2025Type of claim | Amount of claims | In repayment schedule | Disputed | Management board during which the debt was incurred | Representative |
---|---|---|---|---|---|
Tax collector 's claims | ...... € | ...... € | ...... € | ||
Special income tax | ...... € | ...... € | ...... € | ETCB | |
Social tax | ...... € | ...... € | ...... € | ETCB | |
Interest | ...... € | ...... € | ...... € | ETCB | |
Creditors' claims | ...... € | ...... € | ...... € | ||
Total | ...... € | ...... € | ...... € |
GENNET LABORATORIES AS
Time-barred and ongoing claims as of 05.04.2025Sum:
...... €
Sum:
...... €
GENNET LABORATORIES AS
Income (turnover) and expenditure (taxes paid)Quarter | Turnover | Taxed turnover | National taxes paid | Labor taxes paid | Number of employees |
---|---|---|---|---|---|
2024 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2024 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2023 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2022 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2021 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2020 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2019 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2018 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2017 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2016 I | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 IV | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 III | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 II | * ...... € | ...... € | ...... € | ...... € | ...... |
2015 I | * ...... € | ...... € | ...... € | ...... € | ...... |
GENNET LABORATORIES AS
Bailiff's enforcement proceedings as of 05.04.2025Bailiff's enforcement proceedings MISSING
GENNET LABORATORIES AS
Regulations of the Payment Order Department as of 05.04.2025Regulations of the Payment Order Department MISSING
GENNET LABORATORIES AS
Court orders in the register as of 05.04.2025Trahvihoiatusmäärus: majandusaasta aruanne esitamata
Regulation number: Ä 20006100 / M27
Regulation status has entered into force: 07.07.2024
Date of enforcement of order or additional period: 07.07.2024
Regulation status: Jõustunud
Aruandetrahvimäärus
Regulation number: Ä 20006100 / M26
Regulation status has entered into force: 08.12.2023
Date of enforcement of order or additional period: 01.12.2023
Regulation status: Puudused kõrvaldatud
Trahvihoiatusmäärus: majandusaasta aruanne esitamata
Regulation number: Ä 20006100 / M25
Regulation status has entered into force: 23.08.2023
Date of enforcement of order or additional period: 23.08.2023
Regulation status: Jõustunud
Korraldav määrus
Regulation number: Ä 20006100 / M24
Regulation status has entered into force: 31.03.2022
Date of enforcement of order or additional period: 31.03.2022
Regulation status: Jõustunud
Trahvihoiatusmäärus: majandusaasta aruanne esitamata
Regulation number: Ä 20006100 / M23
Regulation status has entered into force: 29.09.2022
Date of enforcement of order or additional period: 16.03.2022
Regulation status: Puudused kõrvaldatud
Puuduste kõrvaldamise määrus
Regulation number: Ä 20006100 / M22
Regulation status has entered into force: 18.03.2021
Date of enforcement of order or additional period: 19.03.2021
Regulation status: Puudused kõrvaldatud
Eitav kandemäärus
Regulation number: K 20006100 / 26
Regulation status has entered into force: 19.02.2021
Date of enforcement of order or additional period: 01.03.2021
Regulation status: Jõustunud
GENNET LABORATORIES AS
Decisions of the Consumer Disputes Committee as of 05.04.2025Consumer disputes MISSING
GENNET LABORATORIES AS
Court hearings as of 05.04.2025Court hearings MISSING
GENNET LABORATORIES AS
Rulings as of 05.04.2025Kohtumäärus haldusasjas nr 3-21-276/9
Tartu Halduskohus Tartu kohtumaja
Related companies: | |
Number of the case: | 3-21-276/9 |
Type of procedure: | Haldusasi |
Court: | Tartu Halduskohus Tartu kohtumaja |
Type of solution: | Kohtumäärus |
Solution subcategory: | Kaebusest loobumise määrus |
Composition of the Court: | Roby Koik |
Commencement of the Court case: | 08.02.2021 |
Type of procedure: | Kohtu I astme menetlus |
Commencement of proceedings: | 08.02.2021 |
Court case category: | Riigihanked, Riigihanked |
Keyword: | - |
Court decision date: | 23.02.2021 |
Entry into force: | 06.03.2021 |
Dissenting opinion: | |
ECLI identifier: ? |
ECLI:EE:TRHK:2021:3.21.276.2851 |
GENNET LABORATORIES AS
Notices and announcements as of 05.04.2025Announcements MISSING
Marketing
Business network
GENNET LABORATORIES AS
Business networkSign in
To expand your connections, log in to the "Networks" environment
Beneficiaries network
GENNET LABORATORIES AS
Networks - BeneficiariesSign in
To expand your connections, log in to the "Networks" environment
Monitoring events
Filter
Dropdown
Dropdown
Neutral
Positive
Negative
No monitoring events found.
Failed to load monitoring events.